- Home
- RGT vs RVPH Comparison
RGT vs RVPH Comparison
Compare RGT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGT | RVPH |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 71.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RGT | RVPH |
|---|---|---|
| Price | $13.17 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.14 |
| AVG Volume (30 Days) | 22.4K | ★ 8.6M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.84 | $0.25 |
| 52 Week High | $11.08 | $2.17 |
Technical Indicators
Market Signals| Indicator | RGT | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.00 | 35.22 |
| Support Level | $12.93 | $0.27 |
| Resistance Level | $13.23 | $0.34 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 88.25 | 17.76 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.